GlassScriptPhysician profile
Yun Hee Ahn
NPI 1215327747
$2,400.70
in general payments reported to CMS, 2019-2025
30 companies · $984 in 2025
The $984 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $86.01 · 2023: $534 · 2024: $585 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $326.49 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $306.81 | 2023-2025 | Zepbound, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $218.08 | 2024-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $195.16 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $182.85 | 2021-2022 | |
| Glaxosmithkline, LLC. | $158.55 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.83 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $113.08 | 2023-2025 | |
| Horizon Therapeutics Plc | $112.95 | 2023 | Krystexxa |
| Inspire Medical Systems, INC. | $101.40 | 2025 | Inspire |
| Exact Sciences Corporation | $68.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $54.78 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $53.47 | 2023 | Xarelto |
| Axsome Therapeutics, INC. | $43.70 | 2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $32.61 | 2024-2025 | Dificid, Lagevrio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.43 | 2022-2023 | Xifaxan, Trulance |
| Philips North America LLC | $30.07 | 2023 | |
| Daiichi Sankyo INC. | $28.82 | 2024 | Injectafer |
| Amgen INC. | $23.99 | 2025 | Krystexxa |
| Dexcom, INC. | $22.50 | 2025 | Dexcom G6 Transmitter |
| Tactile Systems Technology INC | $22.31 | 2023 | Flexitouch Plus, Entre Plus |
| Astellas Pharma US INC | $21.54 | 2025 | Veozah |
| Abbott Laboratories | $20.20 | 2024 | Freestyle Libre 3 |
| Genzyme Corporation | $18.75 | 2024 | |
| Corcept Therapeutics | $18.47 | 2023 | Korlym |
| Idorsia Pharmaceuticals US INC | $17.80 | 2022 | |
| Hikma Pharmaceuticals USA | $14.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.91 | 2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $13.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yun Hee Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.